Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811443 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL12169652 | 0.72 | KMT2A (0.54) | USP2SMN1; SMN2HSD17B10KDM4ECYP1A2 | |
| SCHEMBL17804219 | 0.70 | SMN1; SMN2 (0.42) | USP2SMN1; SMN2HSD17B10KDM4ECYP1A2 | |
| SCHEMBL27852503 | 0.69 | TSHR (0.39) | USP2SMN1; SMN2HSD17B10KDM4ECYP1A2 | |
| SCHEMBL5487333 | 0.66 | ALDH1A1 (0.38) | USP2SMN1; SMN2HSD17B10KDM4ECYP1A2 | |
| SCHEMBL12169765 | 0.66 | USP2 (0.51) | USP2SMN1; SMN2HSD17B10KDM4ECYP1A2 | |
| SCHEMBL28094321 | 0.66 | SMN1; SMN2 (0.41) | USP2SMN1; SMN2HSD17B10KDM4ECYP1A2 | |
| SCHEMBL8893563 | 0.65 | LOX (0.32) | — | |
| SCHEMBL2057187 | 0.65 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL13466370 | 0.64 | ALDH1A1 (0.40) | USP2SMN1; SMN2HSD17B10KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-2016080-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2016080-A4 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | EP | disclosed |
| CN-101432284-A | Dihydropyrazolopyrimidinone derivative | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2016080-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007126122-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | USP2 2983/4885SMN1; SMN2 3943/4885HSD17B10 3046/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | USP2 2983/4885SMN1; SMN2 3943/4885HSD17B10 3046/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | USP2 2983/4885SMN1; SMN2 3943/4885HSD17B10 3046/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | USP2 2983/4885SMN1; SMN2 3943/4885HSD17B10 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.